DNLI - Company ID 0001714899
Denali Therapeutics Inc. trades as DNLI and has a market capitalization of $4.26 B, making it the #1541 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $0.00 and net income of -$512.54M. This page tracks Denali Therapeutics Inc. through 763 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -28.1% to -43.9% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-22 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| 3/A | - | 2026-04-21 |
| Proxy materials | DEFA14A | 2026-04-21 |
| Annual report to shareholders | ARS | 2026-04-21 |
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease | Denali Therapeutics
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights | Denali Therapeutics
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) | Denali Therapeutics
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Denali Therapeutics
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™ | Denali Therapeutics
The largest companies sharing Denali Therapeutics Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Denali Therapeutics Inc. (DNLI) has a market capitalization of $4.26 B as of 2026-07-09, ranking #1541 among US-listed companies.
Denali Therapeutics Inc. reported revenue of $0.00 for fiscal year 2025.
In its latest fiscal year Denali Therapeutics Inc. reported a net loss of $512.54M.